Naringenin: A Promising Therapeutic Agent against Organ Fibrosis

Fibrosis is the final common pathology of most chronic diseases as seen in the heart, liver, lung, kidney, and skin and contributes to nearly half of death in the developed countries. Fibrosis, or scarring, is mainly characterized by the transdifferentiation of fibroblasts into myofibroblasts and th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yanfei Du, Jun Ma, Yu Fan, Xinyu Wang, Shuzhan Zheng, Jian Feng, Jiafu Li, Zhongcai Fan, Guang Li, Qiang Ye
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Cytology QH573-671
Acceso en línea:	https://doaj.org/article/4e6d786fb4d1440299b7020cd8afc664
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e6d786fb4d1440299b7020cd8afc664
record_format	dspace
spelling	oai:doaj.org-article:4e6d786fb4d1440299b7020cd8afc6642021-11-22T01:09:55ZNaringenin: A Promising Therapeutic Agent against Organ Fibrosis1942-099410.1155/2021/1210675https://doaj.org/article/4e6d786fb4d1440299b7020cd8afc6642021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/1210675https://doaj.org/toc/1942-0994Fibrosis is the final common pathology of most chronic diseases as seen in the heart, liver, lung, kidney, and skin and contributes to nearly half of death in the developed countries. Fibrosis, or scarring, is mainly characterized by the transdifferentiation of fibroblasts into myofibroblasts and the excessive accumulation of extracellular matrix (ECM) secreted by myofibroblasts. Despite immense efforts made in the field of organ fibrosis over the past decades and considerable understanding of the occurrence and development of fibrosis gained, there is still lack of an effective treatment for fibrotic diseases. Therefore, identifying a new therapeutic strategy against organ fibrosis is an unmet clinical need. Naringenin, a flavonoid that occurs naturally in citrus fruits, has been found to confer a wide range of pharmacological effects including antioxidant, anti-inflammatory, and anticancer benefits and thus potentially exerting preventive and curative effects on numerous diseases. In addition, emerging evidence has revealed that naringenin can prevent the pathogenesis of fibrosis in vivo and in vitro via the regulation of various pathways that involved signaling molecules such as transforming growth factor-β1/small mother against decapentaplegic protein 3 (TGF-β1/Smad3), mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), sirtuin1 (SIRT1), nuclear factor-kappa B (NF-κB), or reactive oxygen species (ROS). Targeting these profibrotic pathways by naringenin could potentially become a novel therapeutic approach for the management of fibrotic disorders. In this review, we present a comprehensive summary of the antifibrotic roles of naringenin in vivo and in vitro and their underlying mechanisms of action. As a food derived compound, naringenin may serve as a promising drug candidate for the treatment of fibrotic disorders.Yanfei DuJun MaYu FanXinyu WangShuzhan ZhengJian FengJiafu LiZhongcai FanGuang LiQiang YeHindawi LimitedarticleCytologyQH573-671ENOxidative Medicine and Cellular Longevity, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cytology QH573-671
spellingShingle	Cytology QH573-671 Yanfei Du Jun Ma Yu Fan Xinyu Wang Shuzhan Zheng Jian Feng Jiafu Li Zhongcai Fan Guang Li Qiang Ye Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
description	Fibrosis is the final common pathology of most chronic diseases as seen in the heart, liver, lung, kidney, and skin and contributes to nearly half of death in the developed countries. Fibrosis, or scarring, is mainly characterized by the transdifferentiation of fibroblasts into myofibroblasts and the excessive accumulation of extracellular matrix (ECM) secreted by myofibroblasts. Despite immense efforts made in the field of organ fibrosis over the past decades and considerable understanding of the occurrence and development of fibrosis gained, there is still lack of an effective treatment for fibrotic diseases. Therefore, identifying a new therapeutic strategy against organ fibrosis is an unmet clinical need. Naringenin, a flavonoid that occurs naturally in citrus fruits, has been found to confer a wide range of pharmacological effects including antioxidant, anti-inflammatory, and anticancer benefits and thus potentially exerting preventive and curative effects on numerous diseases. In addition, emerging evidence has revealed that naringenin can prevent the pathogenesis of fibrosis in vivo and in vitro via the regulation of various pathways that involved signaling molecules such as transforming growth factor-β1/small mother against decapentaplegic protein 3 (TGF-β1/Smad3), mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), sirtuin1 (SIRT1), nuclear factor-kappa B (NF-κB), or reactive oxygen species (ROS). Targeting these profibrotic pathways by naringenin could potentially become a novel therapeutic approach for the management of fibrotic disorders. In this review, we present a comprehensive summary of the antifibrotic roles of naringenin in vivo and in vitro and their underlying mechanisms of action. As a food derived compound, naringenin may serve as a promising drug candidate for the treatment of fibrotic disorders.
format	article
author	Yanfei Du Jun Ma Yu Fan Xinyu Wang Shuzhan Zheng Jian Feng Jiafu Li Zhongcai Fan Guang Li Qiang Ye
author_facet	Yanfei Du Jun Ma Yu Fan Xinyu Wang Shuzhan Zheng Jian Feng Jiafu Li Zhongcai Fan Guang Li Qiang Ye
author_sort	Yanfei Du
title	Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
title_short	Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
title_full	Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
title_fullStr	Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
title_full_unstemmed	Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
title_sort	naringenin: a promising therapeutic agent against organ fibrosis
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/4e6d786fb4d1440299b7020cd8afc664
work_keys_str_mv	AT yanfeidu naringeninapromisingtherapeuticagentagainstorganfibrosis AT junma naringeninapromisingtherapeuticagentagainstorganfibrosis AT yufan naringeninapromisingtherapeuticagentagainstorganfibrosis AT xinyuwang naringeninapromisingtherapeuticagentagainstorganfibrosis AT shuzhanzheng naringeninapromisingtherapeuticagentagainstorganfibrosis AT jianfeng naringeninapromisingtherapeuticagentagainstorganfibrosis AT jiafuli naringeninapromisingtherapeuticagentagainstorganfibrosis AT zhongcaifan naringeninapromisingtherapeuticagentagainstorganfibrosis AT guangli naringeninapromisingtherapeuticagentagainstorganfibrosis AT qiangye naringeninapromisingtherapeuticagentagainstorganfibrosis
_version_	1718418398339137536

Naringenin: A Promising Therapeutic Agent against Organ Fibrosis

Ejemplares similares